Genenta Science Reports Sustained Survival Benefits in Glioblastoma Trial with Temferon Cell Therapy
Key Insights
Genenta Science's TEM-GBM (search) study shows 44% of glioblastoma patients achieved 18-month survival with Temferon therapy, compared to 38% in the previous data cut.
The trial maintains a 29% two-year survival rate and 17-month median overall survival, substantially outperforming historical standard-of-care outcomes of 14% and 13-15 months respectively.
One patient has reached three years of survival without requiring additional therapeutic interventions, representing a notable milestone in this aggressive brain cancer.
Genenta Science has reported encouraging long-term survival trends from its ongoing TEM-GBM (search) study evaluating Temferon, a novel cell-based therapy, in newly diagnosed glioblastoma multiforme (search) patients with unmethylated MGMT (search) gene promoters. The November 21, 2025 data cut from 25 treated patients demonstrates sustained clinical benefits more than seven months after the previous update.
Survival Metrics Show Continued Promise
The latest analysis reveals that 44% of patients have reached 18-month survival, an improvement from the 38% reported in April 2025. The two-year survival rate remains stable at 29%, with median overall survival maintaining at 17 months. These outcomes compare favorably to historical cohorts of unmethylated MGMT (search) patients treated with standard of care, which typically show approximately 14% two-year survival and 13-15 months median overall survival.
The study has achieved a significant milestone with its first patient reaching three years of survival following Temferon administration, totaling 39 months from initial surgery. During this extended period, the patient required no additional therapeutic interventions or second-line treatments. At the three-year follow-up visit, imaging indicated disease progression, leading to a second surgery, but the patient has continued protocol-scheduled assessments and recently completed the 3.5-year follow-up visit within the Long-Term surveillance study.
Mechanistic Insights from Immune Monitoring
As the first clinical evaluation of Genenta's platform technology, the GBM (search) study provides early observations on Temferon's behavior within the tumor microenvironment. Preliminary findings indicate that bone marrow-derived myeloid cells can successfully reach the tumor site and deliver immunotherapeutic payloads in situ, consistent with the platform's intended design mechanism.
While these immune observations are exploratory and require confirmation in larger controlled studies, they are informing the broader development of Temferon, including potential combination approaches and the evolution of the underlying cell-based delivery technology.
Platform Technology and Development Pipeline
Temferon represents Genenta's proprietary hematopoietic stem cell therapy designed to enable expression of immune-therapeutic payloads within the tumor microenvironment through bone marrow-derived myeloid cells. The therapy aims to reprogram the tumor microenvironment and inhibit myeloid-induced tolerance while inducing T cell responses to potentially break immune tolerance.
Beyond the completed Phase 1 GBM (search) trial, Genenta has initiated a Phase 1/2a study in metastatic renal cell carcinoma (search) that will include combinations with immune checkpoint inhibitors. The treatments are designed as one-time monotherapies with additional potential to enhance the efficacy of other approved therapeutics when used in combination.
Financial Position and Next Steps
Following the October 27 registered direct offering, Genenta held approximately $30 million in cash and short-term investments as of November 1. The company notes that the clinical data presented are preliminary and reflect information collected directly from clinical sites, subject to full quality control review and independent verification by the clinical research organization.